MARKET

ESLAW

ESLAW

Estrella Immunopharma
NASDAQ
0.0760
0.0000
0.00%
Closed 09:30 03/05 EST
OPEN
--
PREV CLOSE
0.0760
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.2400
52 WEEK LOW
0.0305
MARKET CAP
--
P/E (TTM)
-0.2056
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ESLAW last week (0223-0227)?
Weekly Report · 3d ago
Weekly Report: what happened at ESLAW last week (0216-0220)?
Weekly Report · 02/23 09:56
Weekly Report: what happened at ESLAW last week (0209-0213)?
Weekly Report · 02/16 09:56
Estrella Immunopharma Reports 100% Complete Response Rate for EB103 in Phase I B-cell NHL Trial
Reuters · 02/09 12:01
Weekly Report: what happened at ESLAW last week (0202-0206)?
Weekly Report · 02/09 09:57
Estrella Immunopharma Unveils Phase 1 STARLIGHT-1 Data for EB103 in Aggressive B-Cell Lymphoma
Reuters · 02/03 13:02
ESTRELLA IMMUNOPHARMA ANNOUNCES LATE-BREAKING ORAL PRESENTATION OF PHASE 1 STARLIGHT-1 DATA FOR EB103 AT THE 2026 TANDEM MEETINGS OF ASTCT® & CIBMTR®
Reuters · 02/03 13:00
Weekly Report: what happened at ESLAW last week (0126-0130)?
Weekly Report · 02/02 09:57
More
About ESLAW
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.

Webull offers Estrella Immunopharma Inc stock information, including NASDAQ: ESLAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESLAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESLAW stock methods without spending real money on the virtual paper trading platform.